Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: final analyses from INTRIGUE (Slides)

Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: final analyses from INTRIGUE (Poster)

Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.

Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.

Intra-patient dose escalation of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor: Analyses from the phase 3 INVICTUS study.

An open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel in a dose expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.

Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors. ASCO 2017 Annual Meeting, Chicago, Il. Abstract# 2515

Mutation Profile of Drug Resistant GIST Patients Enrolled in the Phase 1 Study of DCC-2618

Safety profile of ripretinib, including impact of alopecia and palmar plantar erythrodysesthesia syndrome (PPES) on patient reported outcomes (PROs), in ≥4th line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS. 

Quality of life (QoL) and self reported function with ripretinib in ≥4th line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.